Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 27, 2011 Brian Orelli	Exelixis 2011: Not What the Doctor Ordered A tale of an inability to get a Special Protocol Assessment from the FDA.
The Motley Fool November 19, 2010 Brian Orelli	Exelixis: Up 32% With Room to Run It was only a phase 2 trial, after all.
The Motley Fool November 1, 2011 Brian Orelli	Not Such an Excellent Outcome With the FDA Exelixis gets knocked down for not getting an SPA.
The Motley Fool May 2, 2011 Brian Orelli	Prostate Cancer Drug Roars Ahead Johnson & Johnson's buy of Cougar paid off, but look in the rear view mirror.
The Motley Fool September 27, 2011 Brian Orelli	Promising Results, But It's Still Early Aeterna Zentaris' investors got a bit of good news yesterday while they wait for phase 3 data for the company's colorectal cancer drug perifosine.
The Motley Fool May 31, 2011 Brian Orelli	5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals.
The Motley Fool October 24, 2011 Brian Orelli	Biotech Blunder Turned 20% Overnight Gain Exelixis gets good data, even if it wasn't exactly what it was expecting.
Chemistry World September 2, 2014 Phillip Broadwith	Exelexis slashes workforce by 70% The move follows poor results from a clinical trial of its cancer drug Cometriq (cabozantinib) in men with metastatic castration-resistant prostate cancer.
The Motley Fool November 3, 2011 David Williamson	Medivation Investors: Why Your Stock Just Jumped 140% Medivation shares pop on trial success for prostate cancer treatment MDV3100.
The Motley Fool February 7, 2011 Brian Orelli	Zibotentan Stopped, Long Live Provenge (for Now) Dendreon is looking good although it's not out of the woods yet.
The Motley Fool June 6, 2011 Luke Timmerman	Exelixis Zeroes In on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients Is Exelixis' risky bet about to pay off?
The Motley Fool May 31, 2011 Brian Orelli	Profit From This Growing Drug Trend Cancer drugs press on.
The Motley Fool May 28, 2010 Brian Orelli	This Drug Doesn't Work. But All Is Not Lost. Novartis cancer drug fails one trial, but there's still hope.
The Motley Fool July 22, 2008 Brian Lawler	Anxiously Awaiting Exelixis Pivotal clinical trial results for a top drug are finally within sight. Investors, take note.
The Motley Fool May 10, 2006 Brian Lawler	Dendreon Drives On Will the FDA say yes to a new cancer drug? Investors, take note.
The Motley Fool December 29, 2011 Brian Orelli	What to Look for From Keryx and Aeterna Zentaris in 2012 The future is uncertain for these pharmaceutical companies.
The Motley Fool March 2, 2011 Brian Orelli	When Will Dendreon Make Money? Not for awhile ... it's a biotech thing.
The Motley Fool May 18, 2011 Brian Orelli	5 Biotech ASCO Abstracts to Watch The biotech investors' Christmas in May is once again upon us, where investors and researchers alike will be able to find the synopsis of what will be presented at the American Society of Clinical Oncology annual meeting next month.
The Motley Fool June 23, 2009 Brian Orelli	Wonder Drug! Maybe? Get the facts before jumping on this one.
The Motley Fool December 21, 2011 Brian Orelli	A Biotech Garage Sale Exelixis sells off a preclinical program.
The Motley Fool January 12, 2004 Dave Marino-Nachison	All Eyes on Dendreon The cancer fighter's shares rocketed today on good news out of Phase III trials.
The Motley Fool October 11, 2010 Brian Orelli	A Dendreon Killer? Not Yet. Johnson & Johnson's abiraterone looks good, but won't knock off the newcomer.
The Motley Fool April 21, 2011 Brian Orelli	Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested.
The Motley Fool December 14, 2010 Brian Orelli	An Ounce of Prevention, a Pound of Blockbuster Sales Amgen's Xgeva recently gained Food and Drug Administration approval to treat cancer patients that have bone metastasis.
The Motley Fool September 2, 2011 Brian Orelli	Delcath Wants a Do-Over You'd think a drug failing to show an effect would be the worst thing that could happen to a biotech investor, but mixed results are actually much worse.
The Motley Fool June 5, 2007 Brian Lawler	Exelixis Presents The pharmaceutical presents data from 2 of its top drug candidates at ASCO. Investors, take note.
The Motley Fool April 28, 2009 Brian Orelli	Headline? Bad! Unexpected? No! For a company that only has one drug on the market, stopping a failing phase 3 clinical trial that's designed to expand the market of that drug is usually a major blow. But Onyx Pharmaceuticals was able to shrug it off.
BusinessWeek October 6, 2003 Gene G. Marcial	Dendreon: New Weapons against Tumors What's so hot about Dendreon, which leaped from 3 last year to 9.25 on Sept. 24? The little-known biotech develops immunologically based cancer remedies, and its lead product, Provenge, is aimed at prostate cancer.
The Motley Fool July 1, 2011 Brian Orelli	Dendreon Is Drama-Free ... for Now For a drug that has had so much drama during its existence, the final decision by the Centers for Medicare and Medicaid Services to pay for Dendreon's prostate cancer treatment Provenge was pretty anticlimactic.
The Motley Fool September 28, 2010 Brian Orelli	Pfizer's Sutent Fails. Again! No surprise here.
The Motley Fool September 10, 2010 Brian D. Pacampara	A Potential Blockbuster Roars Ahead Johnson & Johnson made a good choice to purchase Cougar Biotechnology.
The Motley Fool July 29, 2011 Brian Orelli	2 Biotechs, 1 Promising Cancer Drug Perifosine on the home stretch.
The Motley Fool November 20, 2006 Brian Lawler	One-and-a-Half Setbacks for Exelixis Drug development is a long process usually involving many setbacks and failures, even for the most successful drug makers. Investors in this biotech shouldn't worry too much about this one.
The Motley Fool May 22, 2009 Brian Orelli	J&J and Cougar: Meow or Roar? Health-care giant Johnson & Johnson is doing something that many of its investors -- Buffett included -- wouldn't do; it's buying a development-stage drugmaker that has no proven drugs.
The Motley Fool February 15, 2008 Brian Lawler	Dendreon's Not-So-New Data Development-stage drugmaker Dendreon releases "new data" on lead cancer drug Provenge; unfortunately, the data wasn't the data that investors are waiting for.
The Motley Fool January 11, 2005 Charly Travers	The Future of Cancer Vaccines Biotech companies developing cancer vaccines have been in investors' doghouses for a long time. Can a vaccine help stave off forms of the disease?
The Motley Fool December 31, 2010 Brian Orelli	CEL-SCI Investors Cheer a Bit Too Loudly Finally, a phase 3 trial for cancer therapy Multikine.
The Motley Fool May 10, 2005 Charly Travers	Dendreon in the Spotlight The small biotech's prostate cancer drug is in phase 3 development. Is this company worth investing in?
The Motley Fool October 31, 2008 Brian Orelli	World's Scariest Stock: Dendreon The fear of the unknown makes investing scary, and things don't get much more unknown than the future of biotech company Dendreon.
The Motley Fool October 6, 2011 Brian Orelli	Data Published; Back to Waiting Phase 2 data for Aeterna Zentaris and Keryx's perifosine was published, but it's the phase 3 that's important.
The Motley Fool December 28, 2011 Brian Orelli	Biotech Post-Holiday Regifting A pair of biotechs were on the receiving end of some holiday jeers today as their pharma partners appear to be uninterested in the drugs they were given.
The Motley Fool October 22, 2009 Brian Orelli	Good Luck in 2010, Amgen Just when it looked like Amgen was turning things around the Food and Drug Administration threw a wrench in the biotech's plans for its osteoporosis drug Prolia.
The Motley Fool September 28, 2010 Brian Orelli	It's Up! It's Down! It's Dendreon! The joys of biotech.
The Motley Fool November 28, 2011 Brian Orelli	Breaking Down a Biotech Press Release Aeterna Zentaris: FDA Grants IND to Investigator at Baylor College of Medicine for Phase 2A Trial with AEZS-130 in Cancer Cachexia. That sure is a mouthful. Let's see if we can break it down.
The Motley Fool November 16, 2007 Brian Lawler	Waiting on a Friend for Dendreon Dendreon looks for a marketing partner for a prostate cancer drug that's in clinical trials. Investors, take note.
The Motley Fool March 1, 2007 Brian Lawler	Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works.
The Motley Fool June 18, 2010 Brian Orelli	Double the Approvals! Double the Fun! These twins will take it. sanofi-aventis and Novartis both received FDA approvals for their cancer drugs yesterday.
The Motley Fool May 29, 2009 Brian Orelli	This Company Is Hot and Going Places Pharma company sanofi-aventis licenses a program, including two phase 1 compounds from Exelixis.
The Motley Fool November 10, 2006 Brian Lawler	Dendreon Pending Approval A lot is riding on what the FDA will say about the small pharma's drug for prostate cancer. Investors, take note.
The Motley Fool January 3, 2007 Brian Lawler	Exelixis Busy Selling Its Wares Exelixis inked another development deal with biopharma powerhouse Genentech. Investors, take note.